{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:01:42Z","timestamp":1791388902324,"version":"4.3.3"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.critrevonc.2018.10.011","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T21:54:53Z","timestamp":1541195693000},"page":"85-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["RANK\/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment"],"prefix":"10.1016","volume":"133","author":[{"given":"Peter A.","family":"van Dam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan B.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Lardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-7352","authenticated-orcid":false,"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Baldewijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2018.10.011_bib0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0000000000000459","article-title":"Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center","volume":"22","author":"Afzal","year":"2018","journal-title":"Melanoma Res."},{"issue":"19","key":"10.1016\/j.critrevonc.2018.10.011_bib0010","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","article-title":"Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice","volume":"23","author":"Ahern","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdy050","article-title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumors","volume":"29","author":"Aspelagh","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0020","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.semcancer.2015.02.007","article-title":"Cancer prevention and therapy through the modulation of the tumor microenvironment","volume":"35","author":"Casey","year":"2015","journal-title":"Sem. Cancer Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.10.011_bib0025","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1634\/theoncologist.2010-0154","article-title":"The role of RANK-ligand inhibition in cancer: the story of denosumab","volume":"16","author":"Castellano","year":"2011","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.10.011_bib0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4049\/jimmunol.166.1.270","article-title":"Enhanced secretion of IFN-gamma by activated Th1 cells occurs via reverse signaling through TNF-related activation-induced cytokine","volume":"166","author":"Chen","year":"2001","journal-title":"J. Immunol."},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2018.10.011_bib0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00345-017-2145-y","article-title":"RANKL\/ RANK\/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease","volume":"36","author":"Christoph","year":"2018","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10555-013-9488-7","article-title":"RANK-mediated signaling network and cancer metastasis","volume":"33","author":"Chu","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0045","doi-asserted-by":"crossref","first-page":"S501","DOI":"10.1200\/JCO.2018.36.15_suppl.501","article-title":"Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled study","volume":"36","author":"Coleman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0050","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jcp.2005.030031","article-title":"Expression of receptor activator nuclear factor kappa beta ligand (RANKL) and tumor necrosis factor related apoptosis inducing ligand (TRAIL) in breast cancer, and its relations with osteoprotegrin, estrogen receptor and clinicopathological variables","volume":"59","author":"Cross","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cllc.2015.06.004","article-title":"Therapeutic potential of denosumab in patients with lung cancer: beyond prevention of skeletal complications","volume":"16","author":"De Castro","year":"2015","journal-title":"Clin. Lung Cancer"},{"issue":"January","key":"10.1016\/j.critrevonc.2018.10.011_bib0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review","volume":"62","author":"de Groot","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"March 3","key":"10.1016\/j.critrevonc.2018.10.011_bib0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jtho.2017.11.121","article-title":"RANKL signaling sustains primary tumor growth in genetically engineered mouse models of lung adenocarcinoma","volume":"13","author":"Faget","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2018.10.011_bib0070","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1200\/JCO.2018.36.15_suppl.500","article-title":"Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3425 postmenopausal patients in the ABCSG-18 trial","volume":"218","author":"Gnant","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0075","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1111\/febs.13645","article-title":"RANK as a therapeutic target in cancer","volume":"283","author":"Gonzalez-Suarez","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"issue":"July 27","key":"10.1016\/j.critrevonc.2018.10.011_bib0085","first-page":"42777","article-title":"Osteoprotegerin rich tumor microenvironment: implications in breast cancer","volume":"5; 7","author":"Goswami","year":"2016","journal-title":"Oncotarget"},{"issue":"December12","key":"10.1016\/j.critrevonc.2018.10.011_bib0090","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0095","doi-asserted-by":"crossref","first-page":"S530","DOI":"10.1200\/JCO.2018.36.15_suppl.530","article-title":"Overall survival in female Medicare beneficiaries with early stage breast cancer receiving bisphosphonates or denosumab","volume":"36","author":"Herrera Pena","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.regpep.2008.02.004","article-title":"RANK and RANK ligand expression in thyroid lesions","volume":"148","author":"Heymann","year":"2008","journal-title":"Regul. Pept. Suppl."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0105","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1210\/endo.142.4.8070","article-title":"Determination of three isoforms of the receptor activator of nuclear factor-kappa B ligand and their differential expression in bone and thymus","volume":"142","author":"Ikeda","year":"2001","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.critrevonc.2018.10.011_bib0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.10.011_bib0115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1172\/JCI13890","article-title":"Crystal structure of the TRANCE\/RANKL cytokine reveals determinants of receptor-ligand specificity","volume":"108","author":"Lam","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood-2009-11-255026","article-title":"Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells","volume":"116","author":"Li","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0125","doi-asserted-by":"crossref","first-page":"25328","DOI":"10.18632\/oncotarget.8291","article-title":"CCL20 mediates RANK\/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells","volume":"18","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.10.011_bib0130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4049\/jimmunol.1103387","article-title":"Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin","volume":"189","author":"Luan","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0135","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nm.4076","article-title":"LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption","volume":"22","author":"Luo","year":"2016","journal-title":"Nat. Med."},{"issue":"November1","key":"10.1016\/j.critrevonc.2018.10.011_bib0140","doi-asserted-by":"crossref","first-page":"15683","DOI":"10.1038\/s41598-017-15979-1","article-title":"KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression","volume":"16;7","author":"Ma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12018-015-9188-7","article-title":"The role of estrogen receptor in bone cells","volume":"13","author":"Millian","year":"2015","journal-title":"Clin Rev. Bone Mineral Metab."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0150","doi-asserted-by":"crossref","first-page":"39548","DOI":"10.1074\/jbc.M300539200","article-title":"Vascular endothelial growth factor upregulates expression of receptor activator of NF-kB (RANK) in endothelial cells: concomitant increase of angiogenic responses to RANK ligand","volume":"278","author":"Min","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0155","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.20550","article-title":"Prognostic significance of serum osteoprotegrin levels in patients with bladder carcinoma","volume":"101","author":"Mizutani","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0160","first-page":"1","article-title":"Prognostic Value of Osteoprotegerin and sRANKL in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer","volume":"1047","author":"Naumnik","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.10.011_bib0165","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/0008-5472.CAN-12-0044","article-title":"RANK induces epithelial-mesenchymal transition and stem ness in human mammary epithelial cells and promotes tumorigenesis and metastasis","volume":"72","author":"Palafox","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0170","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/bcr3234","article-title":"Identification of novel human receptor activator of NF-kB isoforms generated through alternative spicing: implications in breast cancer cell survival and migration","volume":"1","author":"Papanastasiou","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cancergen.2017.07.004","article-title":"RANK and EGFR in invasive breast carcinoma","volume":"216-217","author":"Papanastasiou","year":"2018","journal-title":"J. Cancer Genet. Biomark."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.10.011_bib0180","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3346\/jkms.2003.18.4.541","article-title":"Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis","volume":"18","author":"Park","year":"2003","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0185","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/stem.1454","article-title":"Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis","volume":"31","author":"Pellegrini","year":"2013","journal-title":"Stem Cells"},{"issue":"49","key":"10.1016\/j.critrevonc.2018.10.011_bib0190","article-title":"Breast cancer cells stimulate osteoprotegerin production by endothelial cells through direct cell contact","volume":"8","author":"Reid","year":"2009","journal-title":"Moll Cancer"},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0195","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160150","article-title":"RANK-RANKL signaling in cancer","volume":"36","author":"Renema","year":"2016","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0200","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2017-0124","article-title":"The use of combination immunotherapies as front-line therapy for non-small cell lung cancer","author":"Santana-Davila","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0205","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/1940-6207.CAPR-17-0125","article-title":"Circulating RANKL and RANKL\/OPG and breast Cancer risk by ER and PR subtype: results from the EPIC cohort","volume":"10","author":"Sarink","year":"2017","journal-title":"Cancer Prev. Res. Phila. (Phila)"},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0210","doi-asserted-by":"crossref","first-page":"41155","DOI":"10.1074\/jbc.M506366200","article-title":"Functional dissection of osteoprotegerin and its interactions with receptor activator of NF-kappaB ligand","volume":"280","author":"Schneeweis","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0215","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"issue":"January 1","key":"10.1016\/j.critrevonc.2018.10.011_bib0220","doi-asserted-by":"crossref","first-page":"e87204","DOI":"10.1371\/journal.pone.0087204","article-title":"Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells","volume":"22;9","author":"Schultz","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.critrevonc.2018.10.011_bib0225","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.3892\/or.2015.4303","article-title":"RANKL\/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion","volume":"34","author":"Shang","year":"2015","journal-title":"Oncol. Rep."},{"issue":"160230","key":"10.1016\/j.critrevonc.2018.10.011_bib0230","article-title":"RANKL\/RANK: from bone loss to the prevention of breast cancer","volume":"6","author":"Sigl","year":"2016","journal-title":"Open Biol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0235","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.2147\/OTT.S135867","article-title":"The RANK\/RANK\/OPG system in tumorigeneis and metastasis of cancer stem cells: potential targets for anticancer therapy","volume":"10","author":"Sisay","year":"2017","journal-title":"Onco. Ther."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0240","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1200\/JCO.2013.51.3572","article-title":"Combination of anti-CTL-4 and anti-RANKL in metastatic melanoma","volume":"34","author":"Smyth","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0245","article-title":"RANKL promotes migration and invasion of hepatocellular carcinoma cells via NFkB mediated epithelial mesenchymal transition","volume":"9","author":"Song","year":"2014","journal-title":"Plos One"},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0250","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signaling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0255","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bbrc.2011.04.035","article-title":"Hypoxia induces RANK and RANKL expression by activating HIF-1 alpha in breast cancer cells","volume":"408","author":"Tang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0260","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","article-title":"The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiologic bone remodeling","volume":"15","author":"Theolaire","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0265","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.critrevonc.2017.11.001","article-title":"The role of Nuclear Factor-kappa B signaling in human cervical cancer","volume":"120","author":"Tilborghs","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.10.011_bib0270","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.tranon.2017.05.006","article-title":"Evaluation of the prognostic value of RANK, OPG, and RANKL mRNA expression in early breast Cancer patients treated with anthracycline-based adjuvant chemotherapy","volume":"10","author":"Timotheadou","year":"2017","journal-title":"Transl. Oncol."},{"issue":"July 7","key":"10.1016\/j.critrevonc.2018.10.011_bib0275","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1007\/s13277-015-4761-8","article-title":"RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines","volume":"37","author":"Tsubaki","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0280","series-title":"Denys. PRIMMO study: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer","author":"Tuyaerts","year":"2018"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.10.011_bib0285","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.18632\/oncotarget.6667","article-title":"In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment","volume":"7","author":"van Dam","year":"2016","journal-title":"Oncotarget"},{"issue":"December 12","key":"10.1016\/j.critrevonc.2018.10.011_bib0290","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ejso.2017.09.018","article-title":"Neoadjuvant trials can accelerate research on novel systemic treatment modalities in cancer of the uterine cervix","volume":"43","author":"van Dam","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"issue":"June 4","key":"10.1016\/j.critrevonc.2018.10.011_bib0295","article-title":"Potential new biomarkers for squamous carcinoma of the uterine cervix","volume":"28;3","author":"van Dam","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0300","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Seminars Cancer Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.10.011_bib0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0310","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3892\/or.2014.3651","article-title":"MPA influences tumor cell proliferation, migration and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0315","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","article-title":"TRANCE, a new TNF family member predominantly expressed in T cells, is a dendritic cell specific survival factor","volume":"186","author":"Wong","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2018.10.011_bib0320","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.ajpath.2011.02.003","article-title":"RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression","volume":"178","author":"Yamada","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"26","key":"10.1016\/j.critrevonc.2018.10.011_bib0325","doi-asserted-by":"crossref","first-page":"22918","DOI":"10.18632\/oncotarget.4382","article-title":"The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.10.011_bib0330","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3892\/mmr.2017.7039","article-title":"Osteoclast regulation of osteoblasts via RANKRANKL reverse signal transduction in vitro","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."},{"issue":"January 3","key":"10.1016\/j.critrevonc.2018.10.011_bib0335","doi-asserted-by":"crossref","first-page":"e6265","DOI":"10.1590\/1414-431x20176265","article-title":"RANKL expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis","volume":"11;51","author":"Zhang","year":"2018","journal-title":"Braz. J. Med. Biol. Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281830369X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281830369X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:57:08Z","timestamp":1764863828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281830369X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":67,"alternative-id":["S104084281830369X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.10.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RANK\/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}